Form 4: Alkermes Officer Hopkinson Exercises RSUs, Sells Shares

Alkermes plc's EVP R&D and Chief Medical Officer, Craig C. Hopkinson, reported the exercise of restricted stock units and a subsequent sale of ordinary shares.

Summary

• Craig C. Hopkinson, EVP R&D and Chief Medical Officer of Alkermes plc, reported transactions on February 26, 2026.
• Acquired 6,866 ordinary shares upon the exercise/vesting of restricted stock units.
• Disposed of 3,049 ordinary shares at a price of $30.73 per share to cover tax obligations related to the vesting of restricted stock units.
• Following these transactions, Hopkinson directly owns 93,389 ordinary shares.
• Hopkinson also holds 13,732 restricted stock units, each representing a contingent right to receive one ordinary share, with vesting in four equal annual installments commencing on February 26, 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. The vesting of RSUs is a positive for the executive, indicating compensation realization, while the sale for tax purposes is a routine, non-discretionary transaction.

Positives

• The exercise of restricted stock units indicates vesting and value realization for the executive.
• The executive continues to hold a significant number of ordinary shares (93,389) and additional restricted stock units (13,732), demonstrating continued alignment with shareholder interests.

Negatives

• A portion of shares (3,049) was sold, which is a disposition, although it was for tax withholding purposes.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for executives and insiders, reflecting changes in their beneficial ownership. These transactions, particularly those involving RSU vesting and subsequent tax-related sales, are common occurrences in executive compensation structures across the pharmaceutical and biotechnology industries.

Comparison to Industry Standards

• Form 4 filings are standard regulatory disclosures for insider transactions.
• The reported transactions, involving RSU vesting and tax-related sales, align with typical executive compensation practices seen in companies like Pfizer, Johnson & Johnson, or Merck, where equity awards are a significant component of executive pay and often lead to similar reported transactions.

Stakeholder Impact

• Shareholders: Minimal direct impact as these are routine executive compensation transactions. The executive's continued significant ownership aligns interests.
• Employees: No direct impact mentioned.

Next Steps

• Future vesting of the remaining 13,732 restricted stock units in three more equal annual installments, commencing on February 26, 2025 (the first installment already vested on February 26, 2026).

Key Dates

Recommendation

The filing details routine insider transactions related to executive compensation, specifically the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations. These actions are expected and do not indicate a change in the company's fundamental outlook or the executive's long-term commitment. Therefore, the filing itself does not provide new information warranting a change in investment recommendation, suggesting a 'hold' position is appropriate based solely on this disclosure.

Keywords

Alkermes plc, ALKS, Craig C. Hopkinson, Form 4, Insider Trading, Restricted Stock Units, RSU, Share Sale, Executive Compensation, Beneficial Ownership